½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1300815

¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç°º°, Åõ¿© °æ·Îº°, Áúȯ À¯Çüº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Hormone Replacement Therapy Market Size study & Forecast, by Product, by Route of Administration, by Disease Type and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀåÀº 2022³â¿¡ ¾à 212¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 6.6% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

È£¸£¸ó ´ëü¿ä¹ý(HRT)Àº È£¸£¸ó ºÒ±ÕÇüÀ̳ª °áÇÌ¿¡ °ü·ÃµÈ Áõ»óÀ» °ü¸® ¶Ç´Â ¿ÏÈ­Çϱâ À§ÇØ Ã¼³» È£¸£¸óÀ» º¸Ãæ ¶Ç´Â Ä¡È¯ÇÏ´Â ÀÇ·á ÇàÀ§ÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î´Â ¿©¼ºÀÇ °»³â±â Àå¾Ö¿¡ °ü·ÃµÈ Áõ»ó¿¡ ´ëóÇϱâ À§ÇØ »ç¿ëµÇÁö¸¸, ±âŸ Áõ»ó¿¡ ´ëÇؼ­µµ ó¹æµÉ ¼ö ÀÖ½À´Ï´Ù. È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀåÀº È£¸£¸ó Àå¾ÖÀÇ À¯º´·ü »ó½Â ¹× È£¸£¸ó ´ëü¿ä¹ý(HRT)À» ¹Þ´Â ȯÀÚÀÇ Áõ°¡, ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú°³¹ß µîÀÇ ¿äÀο¡ ÀÇÇØ È®´ëÇÏ°í ÀÖ½À´Ï´Ù.

È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀåÀº ´ë»ó ÁúȯÀÇ À¯º´·ü »ó½Â µîÀÇ ¿äÀο¡ ÀÇÇØ È®´ëÇÏ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ °©»ó¼± Çùȸ´Â ¹Ì±¹ÀÎÀÇ 12.0%°¡ ÀÏ»ý Áß ¾î´À ½ÃÁ¡¿¡ °©»ó¼± ÁúȯÀ» °æÇèÇÒ °ÍÀ¸·Î ÃßÁ¤ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2021³â¿¡´Â ¾à 2,000¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ °©»ó¼± Áúȯ¿¡ ÀÌȯÇÑ´Ù°í ¼­¼úÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÇ º¸°í¼­ 2020¿¡¼­´Â ¹Ì±¹ÀÇ Æó°æÈÄ ¿©¼ºÀÇ ¾à Àý¹ÝÀÌ Àû¾îµµ ÇÑ ¹øÀº HRT¸¦ »ç¿ëÇß´ø ÀûÀÌ ÀÖ´Â °ÍÀÌ ¹àÇôÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â 130¸¸ ¸íÀÇ ¿©¼ºÀÌ Æó°æ±â¸¦ ¸ÂÀÌÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ´Ù¾çÇÑ È£¸£¸ó Àå¾ÖÀÇ À¯º´·ü »ó½ÂÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ß ÅõÀÚÀÇ Áõ°¡¿Í È£¸£¸ó °áÇÌÁõ¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»óÀÌ ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÏ°í ÀÖ½À´Ï´Ù. ±×·¯³ª È£¸£¸ó ´ëü¿ä¹ý(HRT)Àº °í¾×À̹ǷΠ2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀåÀÇ ¼ºÀåÀº ÀúÇص˴ϴÙ.

¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå Á¶»ç¿¡¼­ °í·ÁÇÑ ÁÖ¿ä Áö¿ª¿¡´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«°¡ Æ÷ÇԵ˴ϴÙ. ºÏ¹Ì´Â ºê·£µå Á¦Ç°ÀÇ ¿ìÀ§¼º°ú Áö¿ªÀÇ Áúȯ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ 2022³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÃÀå Âü¿© ±â¾÷ÀÇ Áõ°¡, Á¦Ç° °³¹ßÀ» À§ÇÑ Á¦ÈÞÀÇ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ªÀû È®´ë, Á¤ºÎ±â°ü ¹× ºñ¿µ¸®´Üü Àû±ØÀûÀÎ ½ÃÀå Âü¿© µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±ÙÀÇ ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆľÇÇÏ°í, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ¸®Æ÷Æ®´Â Á¶»ç ´ë»ó±¹ »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½ÃÅ°µµ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°øÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÏ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ½º³À¼ô
  • ¼¼°è ½ÃÀ塤ºÎ¹®º° ½ÃÀå Ã߻ꡤ¿¹Ãø, 2020-2030³â
    • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Áö¿ªº°, 2020-2030³â
    • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Á¦Ç°º°, 2020-2030³â
    • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Åõ¿© °æ·Îº°, 2020-2030³â
    • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Áúȯ À¯Çüº°, 2020-2030³â
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå ¿ªÇÐ

  • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • È£¸£¸ó ÁúȯÀÇ À¯º´·ü »ó½Â°ú È£¸£¸ó ´ëü¿ä¹ý(HRT)À» ¹Þ´Â ȯÀÚ ¼öÀÇ Áõ°¡
      • ¾à¹°Àü´Þ ½Ã½ºÅÛ ±â¼ú°³¹ß
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • È£¸£¸ó ´ëü¿ä¹ý(HRT)ÀÇ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • ¿¬±¸°³¹ß ÅõÀÚÀÇ Áõ°¡
      • È£¸£¸ó °áÇÌÁõ¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó

Á¦4Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's 5 Force ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • Æı«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Á¦Ç°º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¿¡½ºÆ®·Î°Õ¡¤ÇÁ·Î°Ô½ºÅ×·Ð º¸Ãæ ¿ä¹ý
    • Àΰ£¼ºÀåÈ£¸£¸ó(HGH) º¸Ãæ ¿ä¹ý
    • °©»ó¼± È£¸£¸ó ´ëü¿ä¹ý(HRT)
    • ³²¼ºÈ£¸£¸ó º¸Ãæ ¿ä¹ý(HRT)
    • ºÎ°©»ó¼±È£¸£¸ó º¸Ãæ ¿ä¹ý(HRT)

Á¦6Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Åõ¿© °æ·Îº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Åõ¿© °æ·Îº°, ½ÇÀû - ÀáÀç ´É·Â ºÐ¼®
  • ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Åõ¿© °æ·Îº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °æ±¸
    • ºñ°æ±¸
    • °æÇÇ
    • ±âŸ

Á¦7Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Áúȯ À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Áúȯ À¯Çüº° ½ÇÀû - ÀáÀç ´É·Â ºÐ¼®
  • ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Áúȯ À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • °»³â±â Àå¾Ö
    • °©»ó¼± ±â´É ÀúÇÏÁõ
    • ³²¼º ¼º¼±±â´ÉÀúÇÏÁõ
    • ¼ºÀåÈ£¸£¸ó °áÇÌÁõ
    • ºÎ°©»ó¼± ±â´É ÀúÇÏÁõ

Á¦8Àå ¼¼°èÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå, Áö¿ª ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå : Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Åõ¿© °æ·Î ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Áúȯ À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ È£¸£¸ó ´ëü¿ä¹ý(HRT) ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Eli Lilly and Company
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¸§)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Bayer AG
    • Noven Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Viatris, Inc.
    • Novo Nordisk A/S
    • F. Hoffmann-La Roche Ltd.
    • ASCEND Therapeutics US, LLC.
    • AbbVie, Inc.

Á¦10Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç ÀüÁ¦Á¶°Ç
KSA 23.08.01

Global Hormone Replacement Therapy Market is valued at approximately USD 21.28 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.6% over the forecast period 2023-2030. Hormone Replacement Therapy (HRT) is a medical treatment that involves supplementing or replacing hormones in the body to manage or alleviate symptoms associated with hormonal imbalances or deficiencies. It is commonly used to address symptoms related to menopause in women, but it can also be prescribed for other conditions. The Hormone Replacement Therapy Market is expanding because of factors such as the rising prevalence of hormonal disorders and increasing number of patients undergoing hormone replacement therapy and technological developments in drug delivery systems.

The market for hormone replacement treatment (HRT) is expanding as a result of factors including the prevalence of target diseases increasing The American Thyroid Association estimates that 12.0% of Americans would l experience thyroid disease at some point in their lives. Additionally, it stated that about 20.0 million Americans suffer from thyroid disease in year 2021. Furthermore, The National Institutes of Health (NIH) report 2020, revealed that nearly half of all post-menopausal women in the US have used HRT at least once. In addition, the report also states that 1.3 million American women are estimated to reach the menopause period each year in the country. Thus, the rising prevalence of various hormonal disorders is fostering market growth. In addition, increasing R&D investments and rising awareness about hormone deficiency is creating a lucrative opportunity for the market. However, the high cost of Hormone Replacement Therapy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hormone Replacement Therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • Eli Lilly and Company
  • Bayer AG
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Viatris, Inc.
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • ASCEND Therapeutics US, LLC.
  • AbbVie, Inc.

Recent Developments in the Market:

  • In November 2022, I-MAB Biopharma Co., Ltd., and Jumpcan Pharmaceutical Group partnered to produce and market eftansomatropin alfa (TJ101) in China. The long-acting recombinant human growth hormone TJ101, which is presently undergoing a phase 3 clinical trial, is being used to treat paediatric growth hormone deficiency.
  • In February 2023, Korea's Ministry of Food and Drug Safety announced the approval of Pfizer's NGENLA for the treatment of hormone deficiency.

Global Hormone Replacement Therapy Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Route of Administration, Disease Type, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Estrogen & Progesterone Replacement Therapy
  • Human Growth Hormone (HGH) Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Replacement Therapy
  • Parathyroid Hormone Replacement

By Route of Administration Type:

  • Oral
  • Parenteral
  • Transdermal
  • Others

By Disease Type:

  • Menopause
  • Hypothyroidism
  • Male hypogonadism
  • Growth hormone deficiency
  • Hypoparathyroidism

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Hormone Replacement Therapy Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Hormone Replacement Therapy Market, by Product, 2020-2030 (USD Billion)
    • 1.2.3. Hormone Replacement Therapy Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.4. Hormone Replacement Therapy Market, by Disease Type, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hormone Replacement Therapy Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hormone Replacement Therapy Market Dynamics

  • 3.1. Hormone Replacement Therapy Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of hormonal disorders and increasing number of patients undergoing hormone replacement therapy
      • 3.1.1.2. Technological developments in drug delivery systems
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Hormone Replacement Therapy
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing R&D investments
      • 3.1.3.2. Rising awareness about hormone deficiency

Chapter 4. Global Hormone Replacement Therapy Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Hormone Replacement Therapy Market, by Product

  • 5.1. Market Snapshot
  • 5.2. Global Hormone Replacement Therapy Market by Product, Performance - Potential Analysis
  • 5.3. Global Hormone Replacement Therapy Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 5.4. Hormone Replacement Therapy Market, Sub Segment Analysis
    • 5.4.1. Estrogen & Progesterone Replacement Therapy
    • 5.4.2. Human Growth Hormone (HGH) Replacement Therapy
    • 5.4.3. Thyroid Hormone Replacement Therapy
    • 5.4.4. Testosterone Replacement Therapy
    • 5.4.5. Parathyroid Hormone Replacement

Chapter 6. Global Hormone Replacement Therapy Market, by Route of Administration

  • 6.1. Market Snapshot
  • 6.2. Global Hormone Replacement Therapy Market by Route of Administration, Performance - Potential Analysis
  • 6.3. Global Hormone Replacement Therapy Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 6.4. Hormone Replacement Therapy Market, Sub Segment Analysis
    • 6.4.1. Oral
    • 6.4.2. Parenteral
    • 6.4.3. Transdermal
    • 6.4.4. Others

Chapter 7. Global Hormone Replacement Therapy Market, by Disease Type

  • 7.1. Market Snapshot
  • 7.2. Global Hormone Replacement Therapy Market by Disease Type, Performance - Potential Analysis
  • 7.3. Global Hormone Replacement Therapy Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
  • 7.4. Hormone Replacement Therapy Market, Sub Segment Analysis
    • 7.4.1. Menopause
    • 7.4.2. Hypothyroidism
    • 7.4.3. Male hypogonadism
    • 7.4.4. Growth hormone deficiency
    • 7.4.5. Hypoparathyroidism

Chapter 8. Global Hormone Replacement Therapy Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Hormone Replacement Therapy Market, Regional Market Snapshot
  • 8.4. North America Hormone Replacement Therapy Market
    • 8.4.1. U.S. Hormone Replacement Therapy Market
      • 8.4.1.1. Product breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Hormone Replacement Therapy Market
  • 8.5. Europe Hormone Replacement Therapy Market Snapshot
    • 8.5.1. U.K. Hormone Replacement Therapy Market
    • 8.5.2. Germany Hormone Replacement Therapy Market
    • 8.5.3. France Hormone Replacement Therapy Market
    • 8.5.4. Spain Hormone Replacement Therapy Market
    • 8.5.5. Italy Hormone Replacement Therapy Market
    • 8.5.6. Rest of Europe Hormone Replacement Therapy Market
  • 8.6. Asia-Pacific Hormone Replacement Therapy Market Snapshot
    • 8.6.1. China Hormone Replacement Therapy Market
    • 8.6.2. India Hormone Replacement Therapy Market
    • 8.6.3. Japan Hormone Replacement Therapy Market
    • 8.6.4. Australia Hormone Replacement Therapy Market
    • 8.6.5. South Korea Hormone Replacement Therapy Market
    • 8.6.6. Rest of Asia Pacific Hormone Replacement Therapy Market
  • 8.7. Latin America Hormone Replacement Therapy Market Snapshot
    • 8.7.1. Brazil Hormone Replacement Therapy Market
    • 8.7.2. Mexico Hormone Replacement Therapy Market
  • 8.8. Middle East & Africa Hormone Replacement Therapy Market
    • 8.8.1. Saudi Arabia Hormone Replacement Therapy Market
    • 8.8.2. South Africa Hormone Replacement Therapy Market
    • 8.8.3. Rest of Middle East & Africa Hormone Replacement Therapy Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Eli Lilly and Company
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Bayer AG
    • 9.3.3. Noven Pharmaceuticals, Inc.
    • 9.3.4. Pfizer Inc.
    • 9.3.5. Merck & Co., Inc.
    • 9.3.6. Viatris, Inc.
    • 9.3.7. Novo Nordisk A/S
    • 9.3.8. F. Hoffmann-La Roche Ltd.
    • 9.3.9. ASCEND Therapeutics US, LLC.
    • 9.3.10. AbbVie, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦